PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program

PTC Therapeutics, Inc. (PTCT) announced positive results on two different long-term extension studies on vatiquinone. The company also announced regulatory progress on vatiquinone for the treatment of Friedreich ataxia (FA). Following the announcement, PTCT stock gained 16.52%. Image Source: Zacks Investment Research Year to date, shares of PTC Therapeutics have risen 48% against the industry's 4.6% decline. PTCT's Vatiquinone Positive in Long-Term Analysis PTCT announced that the pre-specified endpoint for ...